September 19, 2020 14:15 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
IPL 2020 begins today with CSK-MI clash | Karnataka drug scandal: Santosh, Akul, Yuvraj appear before CCB | Kashmir: Suspected militants snatch rifle from bank guard in Pulwama | Kashmir: Three armed Lashkar terrorists arrested in Rajouri | NIA officials arrest 9 Al-Qaeda operatives from West Bengal, Kerala
Dr Reddy's Labs net profit declines 12.6 pc to Rs 579.3 cr in June qtr Dr Reddy's labs

Dr Reddy's Labs net profit declines 12.6 pc to Rs 579.3 cr in June qtr

India Blooms News Service | @indiablooms | 29 Jul 2020, 03:17 pm

Hyderabad/IBNS: Drug manufacturer Dr Reddy's Labs has said its net profit in the June quarter declined 12.60 per cent to Rs 579.3 crore compared with Rs 662.8 crore during the same quarter last month.

The company said its gross margin rose to 56 per cent from 51.7 per cent while its while its revenue from operations rose 15 per cent annually to Rs 4,417.5 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) or operating profit rose 2 per cent to Rs 1,162 crore.

The Hyderabad based company said revenue from India plummeted 10 per cent annually to Rs 630 crore due to lower prescriptions generated and decline in patients visiting clinics and pharmacies.

"The current quarter's financial performance has been strong across all parameter. l am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times. We have started integration and acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets," G V Prasad, co-chairman and managing director of Dr Reddy's labs  said in a statement

Its revenue from North America, its biggest market, rose 6 per cent to Rs 1730 crore, mainly due to new products and favourable foreign exchange rate, which was offset by price erosion.

"Our operations have continued without much impact. We continued our engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued our R&D activities including few projects pertaining to COVID-19," Dr Reddy's Labs said.